Targeting inflammation in AMI: a debate
Sponsored by Novo Nordisk
Coronary Interventions
Other coronary interventions
Pharmacology
Symposium
Drugs and Devices Synergy
Novo Nordisk
Room 243
Anchorperson: Roxana Mehran
Discussants: Davide Capodanno, Wouter Jukema
Watch this session if you want
- To highlight the role of inflammation in AMI, from atherosclerosis through to post-infarct remodeling
- To discuss IL-6 as a key component in the risk of future MACE or worsening of cardiac status in patients with AMI
- To explore the impact and validity of targeting inflammation via IL-6 both in the short and long term
Session objectives
Roxana Mehran
Inflammation in AMI: what do we know?
Roxana Mehran
Is IL-6 a possible target to prevent post-AMI cardiovascular events?
Wouter Jukema
Discussion and audience interaction
Roxana Mehran
Session evaluation and key learnings
Roxana Mehran
